Dogwood Therapeutics Competitors and Similar CompaniesClear all
Dogwood Therapeutics's competitors and similar companies include VCANBIO, Cellares, Acorda Therapeutics and Polyplus-transfection.
 Dogwood Therapeutics Dogwood Therapeutics (formerly known as Virios Therapeutics and Innovative Med Concepts) is a biotechnology company focused on antiviral therapies to treat diseases associated with a virus-triggered abnormal immune response. |  VCANBIO VCANBIO Cell & Gene Engineering (also known as Zhongyuan Union) is a biotech company that offers health management services and products. |  Acorda Therapeutics Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders. |  Polyplus-transfection Polyplus-transfection is a biotechnology company that develops and sells innovative solutions for the delivery of nucleic acids in research, bioproduction, and therapeutics. | ||
Founding Date | Founding Date 2012 | Founding Date 1993 | Founding Date 2019 | Founding Date 1995 | Founding Date 2002 |
Type | Type Public | Type Public | Type Private | Type Public | Type Private |
Tags | |||||
Locations | Locations Alpharetta, US HQ | Locations Tianjin, CN HQ | Locations South San Francisco, US HQ | Locations Ardsley, US HQ Chelsea, US South San Francisco, US Waltham, US | Locations Illkirch-Graffenstaden, FR HQ New York, US |
Employees | Employees 12200% increase | Employees 2,0149% decrease | Employees 2613% increase | Employees 4742% decrease | Employees 1133% increase |
Valuation ($) | Valuation ($) 206.5 k | Valuation ($) 1.4 b | Valuation ($) N/A | Valuation ($) 821 k | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) ¥1.4b (FY, 2025) | Revenue (est.) N/A | Revenue (est.) $117.6m (FY, 2023) | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods ¥438.8m (FY, 2025) | Cost of goods N/A | Cost of goods $15.3m (FY, 2023) | Cost of goods N/A |
Net income | Net income ($34.3m) (FY, 2025) | Net income ¥103.5m (FY, 2025) | Net income N/A | Net income ($252.9m) (FY, 2023) | Net income N/A |
For sources of this data, please see the company profile
View Company Profiles
VCANBIO
HQ
Tianjin, CN
Employees
2,014↓ 9% decrease
VCANBIO Cell & Gene Engineering (also known as Zhongyuan Union) is a biotech company that offers health management services and products.
View company
Cellares
HQ
South San Francisco, US
Employees
261↑ 3% increase
Cellares is a provider of cell therapy manufacturing services.
View companyAcorda Therapeutics
HQ
Ardsley, US
Employees
474↓ 2% decrease
Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders.
View companyPolyplus-transfection
HQ
Illkirch-Graffenstaden, FR
Employees
113↑ 3% increase
Polyplus-transfection is a biotechnology company that develops and sells innovative solutions for the delivery of nucleic acids in research, bioproduction, and therapeutics.
View company